GEIS guidelines for gastrointestinal sarcomas (GIST). (April 2017)

• Record Type: Journal Article
• Authors: Poveda, Andrés; García del Muro, Xavier; López-Guerrero, Jose Antonio; Cubedo, Ricardo; Martínez, Virginia; Romero, Ignacio; Serrano, César; Valverde, Claudia; Martín-Broto, Javier
• Is Part Of: Cancer treatment reviews. Volume 55(2017)
• Page Start: 107
• Page End: 119
• Publication Date: 2017-04
• Subjects: GIST -- Imatinib -- Sunitinib -- Regorafenib -- GEIS -- CD117 -- KIT -- PDGFRA -- DOG1; Cancer -- Periodicals; Cancer -- Treatment -- Periodicals; Neoplasms -- therapy -- Periodicals; Cancer -- Périodiques; Cancer -- Traitement -- Périodiques; Cancer -- Treatment; Electronic journals; Periodicals; 616.99406
• DOI: 10.1016/j.ctrv.2016.11.011
• Languages: English
• ISSNs: 0305-7372

Abstract

Abstract: Gastrointestinal stromal sarcomas (GISTs) are the most common mesenchymal tumours originating in the digestive tract. They have a characteristic morphology, are generally positive for CD117 (c-kit) and are primarily caused by activating mutations in the KIT or PDGFRA genes (1) . On rare occasions, they occur in extravisceral locations such as the omentum, mesentery, pelvis and retroperitoneum. GISTs have become a model of multidisciplinary work in oncology: the participation of several specialties (oncologists, pathologists, surgeons, molecular biologists, radiologists…) has forested advances in the understanding of this tumour and the consolidation of a targeted therapy, imatinib, as the first effective molecular treatment in solid tumours. Following its introduction, median survival of patients with advanced or metastatic GIST increased from 18 to more than 60 months. Sunitinib and Regorafenib are two targeted agents with worldwide approval for second- and third-line treatment, respectively, in metastatic GIST.